This is a first-in-human study to learn more about the investigational drug STX-478. The study will have 3 parts.
Part 1 will study STX-478 as monotherapy in participants with advanced solid tumors. Part 2 will study STX-478 therapy as combination therapy with fulvestrant in participants with hormone receptor positive (HR+) breast cancer. Part 3 will evaluate STX-478 as combination therapy with fulvestrant and a CDK4/6 Inhibitor (either Ribociclib or Palbociclib) in participants with HR+ breast cancer.
Detailed eligibility criteria is available on ClinicalTrials.gov. These requirements will be discussed with your doctor and/or study representative. Visit ClinicalTrials.gov to learn more about this study.
Principal Investigator